

# New MR Probes to Monitor Active Fibrogenesis

**Peter Caravan**

**caravan@nmr.mgh.harvard.edu**


Martinos Center for Biomedical Imaging  
Institute for Innovation in Imaging  
Massachusetts General Hospital  
and Harvard Medical School



# Financial Disclosures


P.C. has equity in Reveal Pharmaceuticals, Factor 1A, LLC and Collagen Medical, LLC. Research support from Pfizer, Indalo, Pliant Consulting income from Guerbet, Bayer

# Lysyl oxidases mediate collagen crosslinking – an active process during fibrogenesis



# Targeting Fibrogenesis


- Active process of fibrotic tissue formation
- Oxidized lysines a product of LOX action on collagen



## Hypothesis:


- Development of a contrast agent that targets oxidized lysine will allow quantification of fibrogenesis by MRI

# Quantification of allysine in tissue




Isolated by prep HPLC  
and characterized by  
NMR and LC-MS



Lung tissue digest



Tissue digest w. standard




Allysine in lung







# Gd-Hyd – a MR probe that detects oxidized collagen

## Desired properties Contrast Agent Design:


- Stable chelate
- Fast blood clearance
- Low non-specific lung uptake
- Hydrophilic and anionic, reduces non-specific binding
- Clearance through renal elimination
- Target selectivity



# Gd-Hyd – a MR probe that detects oxidized collagen



# Gd-Hyd binds oxidized lysine








# Imaging pulmonary fibrosis/fibrogenesis


---

- Standard bleomycin model of pulmonary fibrosis in mice
- Transtracheal bleomycin instillation (or vehicle) followed by imaging and ex vivo analysis at day 7 and day 14
- Evaluate effect of pan-LOX inhibitor BAPN on fibrosis
- Compare active fibrogenesis (2 week post bleomycin) to stable scar (4 week post bleomycin)
- UTE-MRI before and 10 min post Gd-Hyd probe
- Ex vivo: histology, hydroxyproline, LOX activity, allysine (LOX oxidized lysine) content

# Gd-Hyd displays target selectivity in vivo




# Gd-Hyd allows imaging of disease progression




Vehicle

1wk Bleomycin

2wk Bleomycin




# Gd-Hyd imaging analysis correlates with histology and ex-vivo tissue analyses



Statistics: \* ( $P \leq 0.05$ ), \*\* ( $P \leq 0.01$ ) \*\*\*\* ( $P \leq 0.0001$ )





# Effect of LOX inhibition (BAPN) on fibrosis



Statistics: \* (P≤0.05), \*\* (P≤0.01) \*\*\* (P≤0.001)


Chen JCI-Insight 2017;2(11). pii: 91506.

# Effect of LOX inhibition (BAPN) on Gd-Hyd imaging



Statistics: \* (P≤0.05), \*\* (P≤0.01) \*\*\* (P≤0.001)




# Can we distinguish fibrogenesis from stable scar?



Statistics: \* ( $P \leq 0.05$ ), \*\* ( $P \leq 0.01$ ) \*\*\* ( $P \leq 0.001$ )


Chen JCI-Insight 2017;2(11). pii: 91506.

# Gd-OA: Improved allysine targeting





## Gd-OA:

- 2 fold higher affinity than Gd-Hyd
- 2 fold higher reactivity to aldehydes than Gd-Hyd
- 2 fold higher observed relaxivity with oxidized BSA





# Improved in vivo performance



CNR change with Gd-OA is 2-fold higher in diseased animals than with Gd-Hyd

# Kidney fibrosis

---

- Kidney fibrosis occurs in many acute and chronic kidney diseases, and also in transplant
- Fibrosis correlates with poor outcome but no good way to noninvasively assess fibrosis
- Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome
- Mice develop a progressive glomerulonephritis with microhematuria and proteinuria, consistent with the human disease
- Use Gd-OA to identify fibrosis in these mice
- Image before and 4 hours after Gd-OA injection (100  $\mu\text{mol/kg}$ ) at 9.4T; measure T1 and correlate with histology, hydroxyproline, LOX activity, and renal function tests

# Collaborators and Acknowledgements

---

## Massachusetts General Hospital & Harvard Medical School

<u>Group</u>	<u>Alumni</u>	<u>Collaborators – MGH</u>	<u>Support</u>
Zhaoda Zhang	Ritika Uppal	Andy Tager	NHLBI: HL109448
Eszter Boros	Iliyana Atanasova	Sydney Montesi	HL116315
Eric Gale	Daniel Schühle	Kenneth Tanabe	HL131907
Nick Rotile	Phil Waghorn	Bryan Fuchs	NIBIB: EB009062
Pauline Desogere	Howard Chen	Michael Lanuti	NINDS: NS075627
Cynthia Liu	Rich Looby	Chris Farrar	NCI: CA161221
Omar Pinkhasov	Milos Polasek	Alex Guimaraes	<b>NIDDK: DK104302</b>
Diego Ferreira	Huifang Wang	Greg Lauwers	MGH ECOR
Jessica Wahsner	Yan Yang	Mari Mino-Knudson	MGH-MIT
Aurora Rodriguez-Rodriguez		Lida Hariri	Biogen
Junfeng Wang		Iris Chen	Pfizer
Ian Ramsay			Siemens
Chloe Jones			Agilent
Eman Akam			Sanofi
			Pliant
			Indalo